3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
24
CNS
2
Endocrine
1
Conditions
von Hippel-Lindau Disease
2
Pheochromocytoma
2
Paraganglioma
2
Neuroectodermal Tumors, Primitive
1
Hemangioblastoma
1
Carcinoma, Renal Cell
1
Adenoma, Islet Cell
1
Interventions
Everolimus
5
pembrolizumab
2
cabozantinib
2
Trastuzumab
2
Nivolumab
2
vatalanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tipifarnib
1
temsirolimus
1
spartalizumab
1
romidepsin
1
regorafenib
1
pentetreotide
1
guadecitabine
1
fostamatinib
1
exemestane
1
entrectinib
1
entinostat
1
belzutifan
1
avelumab
1
alectinib
1
Vinorelbine
1
Sirolimus
1
Rosiglitazone
1
Ritonavir
1
Radiotherapy
1
Quality of Life
1
Patient Reported Outcome Measures
1
Oxaliplatin
1
Nephrectomy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
belzutifan
×
Endocrine
×
Clear all
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled